Advertisements
Read Time:11 Second
Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from advisers to U.S. regulators, paving the way for a likely full regulatory approval that could lead to broader … Click to Continue »
Happy
0
0 %
Sad
0
0 %
Excited
0
0 %
Sleepy
0
0 %
Angry
0
0 %
Surprise
0
0 %